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ABSTRACT: In this work, we report Mn−Fe heterodoped
ZnSe tetrapod nanocrystals (NCs) synthesized to synergisti-
cally enhance contrast in both T1- and T2-weighted magnetic
resonance imaging (MRI). The proposed NCs were prepared
using a customized heteroarchitecture such that the manganese
(Mn) is confined in the core and iron (Fe) in the branches of
the tetrapods. The elemental composition and profile of these
NCs were studied using X-ray photoelectron spectroscopy,
energy-dispersive X-ray spectroscopy, and inductively coupled
plasma mass spectroscopy. Photoluminescence quantum yield
of these heterodoped NCs in water is ∼30%. Magnetic
measurements reveal the simultaneous presence of super-
paramagnetic and paramagnetic behavior in these NCs because of the coexistence of Mn2+ and Fe2+ dopants. Their potential as
simultaneous positive and negative MRI contrast agents was demonstrated by relaxivity measurements and in vivo MRI. From
the in vivo studies, we also found that these NCs (with a hydrodynamic diameter of 20 nm) are excreted from the body within 24
h after the injection. Therefore, these heterodoped tetrapods NCs, while being fluorescent and safe, hold great future as a
synergistically enhancing dual-modal MRI contrast agent.
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1. INTRODUCTION
Multimodal imaging using nanomaterials integrated with two or
more functionalities is pursued actively worldwide, offering
accurate and reliable tools for medical applications.1,2 Thus, by
integrating the complementary merits of different imaging
modes, accurate and reliable biomedical information can be
obtained. Several multimodal imaging techniques already exist
in the market, for example, positron emission tomography
(PET)/computer tomography (CT) and PET/magnetic
resonance imaging (MRI) are successfully being used clinically
worldwide.3 However, compared to CT, PET, and MRI, optical
imaging (OI) techniques while being low cost are also
promising for revealing biomedical information with high
sensitivity.
Among different kinds of fluorescent materials, quantum dots
(QDs) have been demonstrated as a potential imaging probe
for obtaining detailed subcellular information in vitro.4 QDs
possess exceptional optical features which are mostly controlled
by their size, composition, and surface chemistry.5 Also, when
compared to other classes of fluorescent materials, they exhibit
narrower emission spectra and enhanced stability. However,
fluorescence imaging (FI) suffers from poor spatial resolution
and limited optical penetration depth in the tissue. MRI, on the
other hand, is an important clinical tool for screening the
anatomical details with high resolution. Nevertheless, despite its
three-dimensional imaging capability, the inherent low
sensitivity of the MRI technique demands the use of contrast
agents.
MRI contrast agents are categorized according to their effects
on spin−lattice or longitudinal (T1) and spin−spin or
transversal (T2) relaxations. Superparamagnetic iron oxide
(SPIO) nanoparticles (NPs) are well-known and commercially
available T2 contrast agents.
6 T2 contrast agents are known for
low toxicity and have good biocompatibility, but their intrinsic
dark signal can mislead the clinical diagnosis. In contrast, T1
contrast agents, typically based on paramagnetic (Gd and Mn)
materials,7,8 provide a distinctive resolution between the tissues
because of its high signal intensity. Therefore, it is highly
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desirable to design contrast agents that can synergistically
enhance T1 and T2 contrast in MRI to overcome the
shortcoming of individual contrast agents. Furthermore, the
combination of FI and MRI (both T1- and T2-weighted) offers
robust imaging capabilities that will significantly improve the
detection accuracy in clinical diagnosis. To the best of our
knowledge, there is no commercial probe available in the
market with MRI/FI dual-modal imaging capabilities.
Dual-modal imaging (FI and T1-weighted
7,9 or T2-
weighted10) based on the unification of QDs and magnetic
NPs are of intense interest worldwide among various research
groups. Most of these works use cadmium (Cd)-based QDs for
FI, whereas for MRI, Gd is used for T1-weighted imaging and
SPIO NPs for T2-weighted imaging. Gadolinium (Gd) has been
the most used paramagnetic material for T1-weighted MRI, but
recently it has been associated with a progressive, potentially
fatal multiorgan system fibrosing disease known as nephrogenic
systemic fibrosis (NSF).8 Because of this risk, the U.S. Food
and Drug Administration discourages the use of gadolinium-
based contrast agents in patients who suffer from acute renal
insufficiency.11 Similar to Gd, cadmium is another toxic
element (RoHS, Europe) restricting its usage for applications
linked to human health. These drawbacks led researchers to
work on Cd- and Gd-free materials for dual-modal contrast
agents. As a good alternative to Gd-based MRI contrast agents,
manganese-based NCs are considered safer.8 In this direction,
there are few reports12−15 available in the literature that use
manganese for the combined FI and T1-weighted MRI. Gaceur
et al.13 studied the Zn0.9Mn0.1S NPs and reported their high
relaxivity with a short discussion on the optical performance. In
another study, Ding et al.14 demonstrated FI and MRI
capabilities from the CuInSn2@ZnS:Mn QDs. As a potential
candidate for dual-modal imaging, Mn-doped ZnSe NCs15 have
also been studied.
T1- and T2-weighted MR imaging using nonfluorescent NCs
is not a new field. For example, manganese iron-doped
(MnxFe1−xO) NPs
16−20 have been widely studied by different
groups for positive and negative contrast agents in MRI. In
these doped NPs, high-quality imaging in both T1- and T2-
weighted MRI strongly depend on the dopant concentration.
Recently, it is also pointed out that T1 and T2 contrast agents
should not be in direct contact with each other. Otherwise, the
magnetic field generated by a superparamagnetic (SPM) T2
contrast materials perturbs the relaxation process of the
paramagnetic (PM) T1 contrast material which undesirably
quenches the T1 signal.
21 Considering these issues, researchers
came up with new architectures. One of these designs was
based on the SPM core (T2) and PM shell (T1) structure with a
spacer layer such as silica and platinum between them. Shin et
al.22 used SiO2 as spacer layer in their study and reported that
16 nm silica thickness is adequate between two magnetic
materials to have high T1 and T2 signals. In addition, Cheng et
al.23 synthesized hybrid nanotrimers obtained by combining T1
iron oxide and Gd-coated Au nanocrystals separated by 5 nm
platinum nanocubes. Another design was based on bioconju-
gation of T1- and T2-based materials. Using this architecture,
Bae et al.24 synthesized gadolinium-labeled magnetite nano-
particles for T1- and T2-weighted MRI. However, all these
architectures require complex conjugation steps and synthesis
procedure which results in bigger size, leading to problems in
renal excretion.
In this work, we propose a simple architecture exhibiting
simultaneous T1 and T2 contrast enhancement in MRI. The
schematic of Mn−Fe heterodoped ZnSe nanotetrapod
structure is shown in Figure 1a. In our nanotetrapod design,
Mn sits at the core whereas the Fe is on the branches of these
nanocrystals. Also, to the best of our knowledge, there has been
no report on the fluorescent NCs, which can simultaneously
enhance both T1- and T2-weighted MR imaging. In addition,
these NCs are safer since they are both Cd- and Gd-free.
Moreover, these NCs possess small hydrodynamic diameter
(20 nm) and are easily excreted through the renal system which
is also confirmed by our in vivo studies.
2. EXPERIMENTAL SECTION
Mn−Fe heterodoped ZnSe tetrapod nanocrystals (NCs) are
synthesized using a modified recipe25 and details are provided in the
Supporting Information. UV−vis absorption (Abs) spectra were
obtained using an UV−vis spectrophotometer (Varian Cary 100).
Photoluminescence (PL) spectra of the NCs were obtained with a
fluorescence spectrophotometer (Varian Cary Eclipse). The quantum
yield (QY) of the NCs was measured using Horiba Jobin Yvon time-
resolved fluorescence setup using an integrating sphere F-3018.
Transmission electron microscopy (TEM, Tecnai G2 F30) images
were obtained using a high-resolution transmission electron micro-
scope (HR-TEM) operating at 300 kV. Prior to the imaging, 2 μL of
diluted samples was dropped onto a copper TEM grid and allowed to
dry. Elemental analyses are performed using energy-dispersive X-ray
spectroscopy (EDS), X-ray photoelectron spectroscopy (XPS, Thermo
K-Alpha), and inductively coupled plasma mass spectroscopy (ICP-
MS, Thermo X Series II). All elemental analyses are performed three
times. Fluorescence imaging of NCs drop-casted on the quartz were
obtained using Carl Zeiss Axio Scope Fluorescence Microscope. An
excitation wavelength of 405 nm (LED) (power less than 5 mW) was
used with a 560−600 nm emission pass filter. MRI experiments
(phantom and in vivo) were performed on a 3 T Siemens TrioTim
MR scanner. MRI were acquired using a spin-echo image sequence
(slice thickness = 3 mm, flip angle = 90°, acquisition matrix = 256 ×
256 pixels, field-of-view (FoV) = 90 × 90 mm2, echo time (TE) = 13
ms, repetition time (TR) from 100 to 10 000 ms), where T1 is
extracted by fitting an exponential function to these curves by using
least-squares curve-fitting algorithm.
In Vivo MR Imaging. Animal experiments were performed using a
Sprague-Dawley (200−250 g) rat according to a protocol approved by
the animal ethics committee of Bilkent University, Turkey. MRI
experiments were performed at room temperature on a 3 T Siemens
Figure 1. (a) Schematic of the growth of Mn−Fe heterodoped
tetrapod NCs (yellow color is Mn and red is Fe). TEM images of MZS
NCs obtained after (b) first and (c) second injection of Zn precursor.
(d) TEM image of Mn−Fe heterodoped tetrapod NCs.
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TrioTim MR scanner. T1-weighted and T2-weighted in vivo rat MR
images were acquired using a spin-echo (SE) sequence under the
following parameters: TR/TE = 550/11 ms (T1), TR/TE = 4420/94
ms (T2) (slice thickness = 2 mm, flip angle = 90°, acquisition matrix =
384 pixels × 384 pixels, FoV = 90 × 90 mm2).
Cytotoxicity Studies. To investigate the in vitro cytotoxicity of 3-
mercaptopropionic acid (MPA)-coated water-soluble MFZS tetrapod
NCs, we performed Alamar Blue Assay using L929 mouse cell line.
Before the cell culture study, MFZS NCs were exposed to UV for 45
min for sterilization. Then 2 × 104 L929 cells were seeded into a 96
well plate and waited for 4 h for cell adhesion. MPA-coated MFZS
NCs were added onto the cells with the concentrations of 0, 25, 75,
and 100 μg/mL cells were cultured in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum at 37 °C and
5% CO2 for 24 h. Subsequently, a cell medium was discarded and 200
μL of Alamar Blue solution (10% dye solution in DMEM-high glucose
colorless medium) was added onto the cells. Following 1 h incubation
at 37 °C, the supernatant was transferred into a 96-well plate, and the
absorbances at 570 and 595 nm were measured. A calibration curve
was constructed using known concentrations of cells (L929) to relate
the cell numbers to the dye reduction (%). Statistical analyses were
performed using GraphPad Prism 7, and one-way ANOVA and
Tukey’s multiple comparisons post-tests were employed to determine
the statistical difference of viability in different concentrations.
3. RESULTS AND DISCUSSION
Mn−Fe heterodoped ZnSe (MFZS) tetrapod NCs were
synthesized using modified nucleation doping strategy where
Mn is mostly localized in the core and Fe in the branches. The
schematic of the strategically synthesized nanotetrapods is
shown in Figure 1a. TEM was used to investigate the
morphology and crystal structure of these NCs. Figure 1b,c
shows the TEM images of Mn-doped ZnSe (MZS) NCs
obtained after first and second injection of Zn precursor. It is
observed that after second injection, the shape of NCs has been
deviated from spherical to branched/tetrapods. Figure 1d
represents the TEM image of MFZS NCs after the addition of
Fe into MZS NCs. The branched NCs (nanotetrapods) have an
average size of ∼16 nm, with a core diameter of ∼4.2 nm, a
branch length of ∼5.9 nm, and the thickness of ∼2.5 nm. There
are few reports available in the literature on the varied shaped
MZS NCs.26,27 Wu and Warner26 reported that the shape of the
MZS NCs can be easily tuned between spherical and branched
by controlling the Zn precursor amount and the injection
temperature. According to them, the branching starts
immediately after the first injection of Zn precursor, but can
be controlled by the rate of injection. Similarly, the Peng
group27 reported that the shape of the NCs can be altered
between sphere and tetrapods by varying the concentration of
fatty acids and fatty amines. In both of the references
mentioned above, Mn was localized in the core. We believe
that, in our case, the Zn precursor amount together with the
rate of injection resulted in tetrapod shapes. The proposed
atomic model for tetrapod shapes of the MZS NCs is described
in detail in our previous study.25 Also, the shape of the NCs was
already tetrapods25,28 before the introduction of Fe as observed
in our case as well. Thus, we believe that Fe is present on the
branches of the NCs. This has been further confirmed with the
energy-dispersive X-ray spectroscopy measurements in con-
junction with HR-TEM.
Figure 2 shows a HR-TEM and spatially resolved elemental
data (EDS) analysis of tetrapod NCs. The EDS spectra of the
core (A) and branch (B) areas are obtained and the Mn or Fe
to Zn molar ratio (Mn/Zn or Mn/Fe) are shown in the inset of
Figure 2. Results reveal that Mn was detected only in the core
area of the tetrapods whereas Fe is observed in the branches of
the tetrapod NCs. Our synthesis strategy in conjunction with
the results conclude that Fe is mostly located at the edges of the
nanotetrapods (represented by red color in the schematics).
We have carried out a detailed selected area electron
diffraction (SAED) investigation to probe the crystal structure
and impurity phases in these NCs. The SAED pattern of MZS
NCs obtained before and after Fe doping is shown in Figure S1
(see Supporting Information). Clear nanocrystalline rings were
observed for MZS NCs which can be indexed to the ZB (zinc
blende) phase of ZnSe. However, we do not observe any new
phase from the SAED pattern of MFZS NCs obtained after Fe
doping, suggesting that Fe is doped into MZS NCs.
We have performed a detailed elemental characterization of
these NCs using EDS, ICP-MS, and XPS to establish the
location and concentration of Mn and Fe in these NCs. Three
sets of measurements have been taken for all the character-
izations and the average and standard deviation (SD) data are
presented in Table 1. EDS has been used in conjunction with
TEM to ascertain the location of Mn and Fe in the NCs. The
results demonstrated that the Mn is in the core, whereas Fe is
mostly localized in the shell (Figure 2). The corresponding
Mn/Fe ratio in the MFZS NCs obtained using EDS and ICP-
MS techniques are quite similar, which is expected. EDS and
ICP-MS techniques provide the overall ratio of the two cations
in the sample; therefore, the observed Mn/Fe ratio should be
close to the actual value. On the other hand, XPS, which is a
surface-sensitive technique, shows (lower Mn/Fe ratio value
compared to EDS and ICP-MS) consistency with the targeted
core−shell structure and proves that Mn atoms are confined in
the core whereas Fe is mostly found in the shell. The reason for
difference in Mn/Fe ratio between XPS and other techniques
(EDS and ICP-MS) is most probably due to the tetrapod
geometry of the NCs. Since one of their branches is always in
the up direction, it is expected to observe more Fe than Mn in
Figure 2. HR-TEM image of the Mn−Fe heterodoped ZnSe tetrapod
NCs along with EDS data.
Table 1. Elemental Data Obtained by EDS, ICP-MS, and
XPS of MFZS NCs
techniques Mn (at. %) Fe (at. %) SD (at. %) Mn/Fe
EDS 4.8 2.9 0.37 1.65
ICP-MS 3.1 1.7 0.16 1.82
XPS 3.7 4.6 0.48 0.80
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XPS data. For this reason, we take account of these results of
the ICP-MS measurement and find that the actual value of Mn
and Fe concentration is 3.1 and 1.7 at. % in these NCs,
respectively. In our previous study, we have found that the Mn
concentration of 3.2 at. % is the optimum where we have
highest efficiency for MZS NCs.15 Photoluminescence studies
of MFZS NCs with different Fe doping concentrations has
been carried out and is presented in Figure S2 of the
Supporting Information. On the basis of this data, it is found
that Fe concentration of 1.7 at. % in MFZS NCs is optimum for
high FI and MRI.
PL studies of all the NCs were carried out by a 300 nm
excitation source and are shown in Figure 3. PL spectra of MZS
NCs show a broad emission band at 583 nm with a full-width at
half-maximum (fwhm) of ∼52 ± 1 nm, which is attributed to
the 4T1 to
6A1 transition in Mn
2+.29 We only observe the pure
Mn-doped emission without any band edge emission
originating from ZnSe, thus confirming that Mn2+ is
successfully incorporated into ZnSe host. After the doping of
Fe into the MZS NCs, we observed a decrease in the intensity
of the Mn-doped emission with the additional appearance of
emission from ZnSe band gap. Fe doping is popularly known
for quenching the emission in ZnSe and ZnS nanocrystals.30−32
It is believed that after the Fe introduction, the Mn-doped
emission intensity decreases because the absorbed energy is
transferred from Mn2+ ions to the quenching centers such as
Fe2+-related centers and surface state.31 It is known that in bulk
Fe-doped ZnS,30 Fe atoms act as electron-trapping centers
which results in nonradiative recombination. In our case, we
observe quenching in the emission as well. In the literature,
there is no consensus on the Fe2+-related emission; that is, Cao
et al.33 reported 490 nm whereas Kang et al.34 attribute 520 nm
emission to the iron doping in ZnS nanowires. Moreover, some
groups reported that they do not observe any emission in the
visible range in Fe-doped ZnS NCs.31,32,35,36 In our case, we
also did not obtain any Fe-related emission, but we observe
quenching in the emission of Mn-doped NCs after Fe
introduction. These results suggest that Fe is doped successfully
into the ZnSe NCs which is also confirmed by SAED pattern
and elemental studies. After the last shell of ZnSe is deposited,
the doped PL emission has been recovered with no emission
from the ZnSe band gap. Therefore, we confirm that both Mn
and Fe are doped into the ZnSe NCs.
PL QY measurements performed by an integrating sphere
revealed ∼23% efficiency for the MFZS NCs. Water-soluble
NCs were obtained by ligand exchange (see Supporting
Information for details) for biomedical applications. These
NCs showed excellent colloidal stability in water with the
hydrodynamic diameter of 20.6 nm, as measured by dynamic
light scattering (DLS) (see Figure S3 of the Supporting
Information). The comparative PL spectra (and absorption
spectra) of the MFZS NCs dissolved in toluene and water are
presented in Figure S4 of the Supporting Information. The PL
emission peak shifted by 5 nm (from 583 to 588 nm) after the
ligand exchange, having a similar fwhm. Interestingly, QY of
these NCs increases to ∼30% in water after ligand exchange
from toluene, which is quite contradictory to what is reported
in the literature.12 We believe that, in our case, it may be
because of an additional ZnS shell formed on the MFZS NCs
after the ligand exchange. Because our synthesis procedure
includes an excess amount of Zn and this may possibly form
ZnS by reacting with MPA. The formation of this possible ZnS
shell on these NCs has been confirmed by XPS as shown in
Figure 4. The peaks at 160.0 and 165.6 eV correspond to Se 3p
doublet transitions, and the peaks at 161.7 and 163.5 eV
correspond to S 2p doublet transitions. The XPS data are
consistent with the previous reports on the core−shell NCs.37
The 5 nm red shift in the PL peak after ligand exchange also
supports this hypothesis.
The field-dependent magnetic properties (M−H curve) of
these NCs were measured using a physical property measure-
ment system (PPMS) at body temperature (310 K). M−H
curve of MZS NCs shows paramagnetic (PM) behavior (Figure
5a), whereas iron codoping introduces SPM (Figure 5b)
behavior to the inherent PM behavior of these NCs. M−H data
(Figure 5b) of MFZS NCs reveals that the magnetization is
continuously increasing with the applied field, most probably
because of the competing paramagnetic (PM) and SPM
interactions resulting from the doping of Mn and Fe into
these NCs. Also, there is a tenfold increase in the magnetization
after the introduction of Fe into the MZS NCs. Therefore, we
believe that the MFZS NCs possess mixed magnetic (PM and
SPM) phases simultaneously. The presence of mixed magnetic
(SPM + PM) phases in these NCs is substantiated by fitting the
M−H curve of Figure 5b with the relation below,
Figure 3. Photoluminescence spectra of the NCs excited at 300 nm.
Figure 4. High-resolution XPS spectrum of water-soluble MFZS NCs
obtained after the ligand exchange.
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where kB is the Boltzmann constant, M(T) is the temperature-
dependent magnetization, Ms is the saturation magnetization, μ
is the magnetic moment, and χ is the susceptibility of the NCs.
The first and second term in eq 1 represents the SPM and PM
contribution, respectively. The fit obtained by using eq 1 (red
color in Figure 5b) is in complete agreement with the
experimental data, confirming the simultaneous presence of
SPM and PM magnetic phases in the MFZS NCs. Therefore,
we would expect simultaneous contrast enhancement in T1-
and T2-weighted MR images similar to MnFeO
19 and GdFeO38
NPs.
T1 and T2 relaxation efficiencies of the water-soluble
fluorescent MFZS NCs were obtained from the phantom
imaging experiments performed using a 3T Siemens MR
Scanner. Prior to the imaging, we calculated the concentrations
of Mn and Fe within MFZS NCs using ICP-MS and prepared
four samples with different concentrations. T1- and T2-weighted
phantom images of these samples and DI water are shown in
Figure 6a,b. The increase in the intensity of bright contrast with
the increased Mn concentration is clearly observed for T1-
weighted MR phantom images. Similarly, a clear decrease in the
intensity of dark contrast with increasing concentration of Fe
has been observed for T2-weighted MR images. Thus, phantom
results confirm the simultaneous contrast enhancement in T1-
and T2-weighted MR images using MFZS NCs.
The longitudinal (r1) and transverse (r2) relaxivities were







where T0 and T1,2 are the longitudinal and transverse relaxation
times of DI water and the MFZS NCs, respectively.
The longitudinal (r1) and transverse (r2) relaxivities for the
MFZS NCs were obtained from the slope of (1/T1,2 − 1/T0) vs
Mn/Fe concentration (Figure 7a,b), and are found to be 2.2
and 47.5 mM−1 s−1, respectively. The r1 relaxivity value of 2.2
mM−1 s−1 for these NCs is due to the large number of Mn2+
ions with five unpaired electrons. These values are somewhat
similar to the clinically available gadolinium-based MRI contrast
agents (∼4 mM−1 s−1),40 thus offering promising substitutes to
these contrast agents which are associated with NSF. Our
MFZS NCs also exhibit T2 relaxivity because of the presence of
Fe2+ ions which introduces the SPM behavior in these NCs.
Resovist41 is a well-known commercially available T2 contrasts
agent with (hydrodynamic size ∼60 nm) r2 relaxivity as high as
∼150 mM−1 s−1. Relaxivity values of our NCs are lower since
their sizes were one-third of the Resovist sizes. The advantage
of being smaller in size will help with the clearance of these
NCs from the body which is discussed in detail in the next
section. From Figure 6, we clearly observe increased (bright)
and reduced (dark) signals intensities in T1- and T2-weighted
MR images using MFZS NCs by increasing the concentration
of Mn2+ and Fe2+, respectively. These results substantiate that
these NCs can simultaneously act as both negative and positive
MR contrast agents. Moreover, these NCs exhibit high PL QY
(∼30%), which can be used as a complementary tool for
obtaining detailed information for accurate medical diagnosis
along with MRI. A fluorescence image of these NCs is taken
with 405 nm excitation wavelength and is presented in the
Supporting Information as Figure S5 to demonstrate their
fluorescence imaging capabilities.
The in vitro cytotoxicity of MPA-coated MFZS NCs was
investigated using the L929 mouse cell line with the
concentrations of 0, 25, 50, 75, and 100 μg/mL. No appreciable
toxicity was observed up to the concentrations of 100 μg/mL as
shown in Figure 8. The result of cell assays confirmed that
these NCs are not cytotoxic, up to high concentrations of 100
μg/mL.
We have further demonstrated the in vivo T1-weighted
(Figure 9a) and T2-weighted (Figure 9b) MR imaging of blood
vessels and kidneys using MFZS NCs. For in vivo MR imaging,
T1 and T2 abdominal imaging before and after injection was
Figure 5. M−H curve of (a) MZS and (b) MFZS NCs.
Figure 6. T1- and T2-weighted MR phantom images of the MFZS
NCs.
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conducted by using a 3T MR scanner. To observe the effect of
our contrast agent, MFZS NCs were injected intravenously
(dosage ∼1 mg kg−1) into a Sprague-Dawley rat. The coronal
images of blood vessels and kidney were recorded before the
injection and after 5, 30, and 60 min following the injection.
Abdominal MR images taken at postinjection time demon-
strated that the veins carrying blood to kidneys and kidney itself
progressively turned to brighter and darker in T1 and T2
coronal planes, respectively. The removal of NCs from the
body was investigated by comparing the MR images of the rat
at the same position (kidneys) after 24 h. The signal changes in
kidneys and blood vessels obtained by both T1- and T2-
weighted MR imaging suggest that these NCs were removed
from the body within 24 h.
Investigation of the biocompatibility and biodistribution of
the nanoparticles is very crucial for the biological applications.
In general, the biodistribution and clearance mechanisms of the
Figure 7. (a) T1 and (b) T2 relaxivity plots of the MFZS NCs obtained at 3 T @ 25 °C.
Figure 8. Viability of L929 cell line treated with the MFZS tetrapod
NCs for 24 h (ns, nonsignificant).
Figure 9. (a) T1- and (b) T2-weighted MR images of rat abdomen showing kidneys before MFZS NCs injection and 5, 30, and 60 min after injection
at room temperature. Region of interests have been marked by the orange arrow.
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NCs are related to the size, morphology, and surface
characteristics together with their degradation duration within
the physiological environment.42 In the literature, a broad range
of QD types were investigated for their potential toxicity along
with their distribution and clearance in animal models.43−45 For
example, Hauck et al. studied the toxic effect of CdSe/ZnS
core−shell QDs in rats along with their biodistribution and
reported that there is no toxic effect even after the degradation
of the QDs.46 In another report, a pilot study carried out with
rhesus macaques demonstrated that intravenously injected
phospholipid micelle-encapsulated CdSe/CdSZnS QDs have
no toxic effect. This study showed that the QD concentration
was much higher in the liver, spleen, and kidney in the primates
compared to those in the rats.44 The effect of nanoparticle size
on the clearance of QDs were also studied by Gao et al.47 In
this study, two different carboxylate-coated InAs/InPZnSe QDs
with the hydrodynamic diameters of ca. 25 (QD800-COOH)
and 10 nm (QD800-MPA) were used. Results demonstrated
that QD800-MPA were excreted from the body more efficiently
compared to the larger QD800-COOH nanoparticles.
Furthermore, PL intensity of the smaller QDs gradually
decreased in the kidney with time, which suggests renal
removal of nanoparticles. In addition to size, surface coating is
another important factor affecting the particle excretion. Fischer
et al. injected CdSe/ZnS QDs having different coatings such as
MPA, lysine, or bovine serum albumin (BSA) and found
different distributions based on the coatings. They reported
that MPA-coated QDs are taken up more by the lung and
kidney compared to the BSA-coated QDs.48
In our in vivo experiments, we used MPA-linked MFZS NCs
with a hydrodynamic diameter (HD) of 20.6 nm. In the light of
the literature, we can attribute the renal clearance of the NCs to
the MPA ligands together with their smaller size. Moreover,
intravenous injection49 may possibly trigger the fast renal
excretion of MFZS NCs from the rat within 24 h. However, to
investigate the distribution of the NCs to the other tissues such
as liver, lung, and spleen, more detailed biodistribution study is
required, which may help to understand the clearance
mechanism of MFZS NCs in detail.
These results confirm that MFZS NCs are potential contrast
agents for MRI, owing to their designed architecture resulting
in contrast enhancement in both T1- and T2-weighted imaging.
Moreover, these NCs possess high PL QY ∼ 30% in addition to
their T1- and T2-weighted MRI capabilities, which in turn
provide detailed information for accurate clinical diagnosis.
4. CONCLUSION
In summary, we have demonstrated that fluorescent MFZS
tetrapod NCs can simultaneously enhance contrast in both T1-
and T2-weighted MR images. They exhibit high QY (∼30% in
water) for FI and r1 and r2 relaxivities values of ∼2.2 and ∼47.5
mM−1 s−1 for MRI. Magnetic characterization reveals the
simultaneous presence of superparamagnetic and paramagnetic
phases in these NCs that triggers simultaneous T1 and T2
contrast enhancement. These NCs possess small hydrodynamic
diameter (∼20 nm) and are excreted from the body within 24 h
following the injection. Thus, these NCs possess potential for
accurate clinical diagnosis using dual mode (T1- and T2-
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